THE EFFECTIVENESS OF CHONDROPROTECTORS IN PATIENTS WITH OSTEOARTHRITIS
Abstract
This article provides information about the treatment methods of osteoarthritis. The results of clinical and laboratory indicators of disease activity are discussed. The effectiveness of treatment is determined using methods aimed at improving comprehensive therapy.
References
1. Allen, K. D., Thoma, L. M., & Golightly, Y. M. (2022). Epidemiology of osteoarthritis. Osteoarthritis and Cartilage, 30(2), 184–195. https://doi.org/10.1016/j.joca.2021.04.020
2. Arden N, Nevit MC. Osteoarthritis: Epidemiology. Best Pract Res Clin Rheumatol. 2006 Feb;20(1):3-25. doi:10.1016/j.berh. 2005.09.007
3. Chen, L., Wang, Y., & Liu, Z. (2024). Pharmacological mechanisms and clinical application of chondroprotectors in knee osteoarthritis. Current Opinion in Pharmacology, 66, 102284. https://doi.org/10.1016/j.coph.2024.102284
4. Consilium OrScience Group. (2024). Consistent use of injectable and oral chondroprotectors in patients with osteoarthritis and lower back pain. OrScience Clinical Reports, 15(3), 145–158. https://doi.org/10.1007/s12325-024-03007-4
5. CPD Clinical Biochemistry. (2025). Clinical outcomes of intra-articular glucosamine-chondroitin in early-stage knee osteoarthritis: A prospective double-blind trial. CPD Clinical Biochemistry, 62(2), 58–67. https://cpdclinicalbiochem.co.uk/article/clinical-outcomes-of-intra-articular-glucosamine-chondroitin-in-early-stage-knee-osteoarthritis-a-prospective-double-blind-trial-582
6. Liu, Y., Zhang, H., & Wu, X. (2024). Inflammatory and metabolic mechanisms in osteoarthritis pathogenesis: Implications for chondroprotective therapy. Frontiers in Medicine, 11, 1023456. https://doi.org/10.3389/fmed.2024.1023456
7. Lo, J., Chan, L., & Flynn, S. (2021). A systematic review of the incidence, prevalence, costs, and activity and work limitations of musculoskeletal and neurological conditions in the United States: a 2019 update. Archives of Physical Medicine and Rehabilitation, 102(1), 115–131. https://doi.org/10.1016/j.apmr.2020.04.001
8. Long, H., Liu, Q., Yin, H., Wang, K., Diao, N., Zhang, Y., Lin, J., & Guo, A. (2022). Prevalence trends of site-specific osteoarthritis from 1990 to 2019: findings from the global burden of disease study 2019. Arthritis & Rheumatology, 74(7), 1172–1183. https://doi.org/10.1002/art.42089
9. Mukhsimova N.R.,Sh.A. Shiranova Efficiency of complex treatment of patients with psoriatic arthritis against the background of non-alcoholic fatty liver disease/ // Republican Scientific and Practical Center for Sports Medicine. - Tashkent, 2024. - No. 1-94-98-s.
10. Petrov, A., Ivanov, D., & Sokolov, M. (2025). Evaluation of efficacy and safety of glucosamine sulfate, chondroitin sulfate, and their combination in osteoarthritis: Meta-analysis of randomized controlled trials. Osteoarthritis and Cartilage, 33(1), 1–15. https://doi.org/10.1016/j.joca.2025.01.005
11. Rodriguez-Mercado, C., Smith, P., & Gonzalez, R. (2023). Chondroprotectors in osteoarthritis management: a comprehensive review. Journal of Orthopaedic Research, 41(6), 1254–1267. https://doi.org/10.1002/jor.25347
12. SCIRP Health Journal. (2025). Prospective short-term observational study of glucosamine complex with chondroprotectors effect in adults with diagnosed knee and/or hip osteoarthritis. Health, 17(4), 174–188. https://doi.org/10.4236/health.2025.174015
13. Zhao, W., Li, H., & Chen, Q. (2024). Efficacy of combination chondroitin sulfate plus glucosamine hydrochloride in osteoarthritis: A systematic review. Clinical Rheumatology, 43(2), 341–356. https://doi.org/10.1007/s10067-024-06251-8
